Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6502718 | 0.95 | MAPT (0.44) | SMN1; SMN2MAPTAURKAKDM4ELMNA | |
| SCHEMBL6501863 | 0.93 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9ARXFP1CYP1A2 | |
| SCHEMBL6492199 | 0.93 | TP53 (0.46) | NPC1RAB9ARXFP1MAPTKDM4E | |
| SCHEMBL6499318 | 0.90 | MAPT (0.49) | SMN1; SMN2NPC1RAB9ARXFP1MAPT | |
| SCHEMBL6502572 | 0.88 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ARXFP1MAPT | |
| SCHEMBL6500236 | 0.88 | GCGR (0.49) | SMN1; SMN2NPC1RAB9ARXFP1MAPT | |
| SCHEMBL6489237 | 0.85 | MAPT (0.46) | SMN1; SMN2NPC1RAB9ARXFP1MAPT | |
| SCHEMBL6647756 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9ARXFP1CYP1A2 | |
| SCHEMBL6501928 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ARXFP1MAPT | |
| SCHEMBL6649517 | 0.83 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9ARXFP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | SMN1; SMN2 1921/4885NPC1 100/4885RAB9A 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.